NextCure (NASDAQ:NXTC) Stock Price Down 3.6% – Time to Sell?

Shares of NextCure, Inc. (NASDAQ:NXTC) were down 3.6% during mid-day trading on Wednesday . The stock traded as low as $1.34 and last traded at $1.35. Approximately 9,600 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 126,214 shares. The stock had previously closed at $1.40.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of NextCure in a research note on Friday, August 2nd.

NextCure Stock Performance

The stock’s 50 day moving average is $1.41 and its 200-day moving average is $1.50.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). As a group, equities analysts forecast that NextCure, Inc. will post -1.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Logos Global Management LP raised its holdings in shares of NextCure by 29.9% in the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after buying an additional 575,000 shares during the period. Armistice Capital LLC bought a new position in NextCure in the 2nd quarter valued at $57,000. Affinity Asset Advisors LLC lifted its position in shares of NextCure by 24.2% during the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock worth $2,684,000 after purchasing an additional 328,918 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of NextCure by 15.4% during the second quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after purchasing an additional 61,744 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of NextCure by 9.3% in the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after purchasing an additional 83,700 shares during the last quarter. 42.65% of the stock is owned by hedge funds and other institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.